Test results for Bayetta-like therapies for T2 presented at the EASD

Test results for Bayetta-like therapies for T2 presented at the EASD
See the free downloads of the Online Scientific Programme incl. abstracts

http://www.easd.org/
42nd EASD Annual Meeting 2006, Copenhagen-Malmoe Thursday, 14 September -
Sunday, 17 September 2006

There are new devellopments for the GLP-1 target.Both stable analogs of
GLP-1 and DPP inhibitors (The enzyme that breaks GLP-1 down):

http://investors.amylin.com/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=905258&highlight=
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic
Insulin Aspart
- Patients on exenatide lost weight, while insulin aspart patients gained
weight -

COPENHAGEN, Denmark, Sept. 14 /PRNewswire-FirstCall/ -- Eli Lilly and
Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today
announced results from a study indicating that exenatide improves blood
sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30(R),
NovoNordisk) for people with type 2 diabetes failing to achieve acceptable
blood sugar control on both metformin and a sulfonylurea, two common oral
diabetes medications. This long-term clinical trial is the second study
conducted at European clinical centers demonstrating that exenatide can
control blood sugar as effectively as insulin.(1)



http://www.merck.com/newsroom/press_releases/research_and_development/2006_0613.html
In New Data at One Year, JANUVIAT, an Investigational Once-Daily Medicine
for Type 2 Diabetes, Demonstrated Substantial Glucose-Lowering Effect, With
Significant Differences Compared to Glipizide (a Sulfonylurea) in Weight
Change and Hypoglycemia
In This Non-Inferiority Study, the Reduction in A1C Was Identical Between
the Two Groups at 52 Weeks; Also, Patients on JANUVIA had Significant Weight
Loss (vs. Weight Gain on Glipizide) and a Significantly Lower Incidence of
Hypoglycemia vs. Glipizide

WASHINGTON, D.C., June 13, 2006 - In a late-breaking oral presentation here
today at the American Diabetes Association (ADA) 66th Annual Scientific
Sessions, results from a non-inferiority study comparing JANUVIAT
(sitagliptin phosphate) to glipizide (a sulfonylurea) showed JANUVIA was
non-inferior to glipizide in significantly reducing blood sugar (glucose)
levels at 52 weeks when added to the regimen of patients with type 2
diabetes who had inadequate control on metformin monotherapy. The 52-week
data presented were the primary time point analysis for this study, which
continues for another year (through 104 weeks). JANUVIA is Merck and Co.,
Inc.'s investigational once-daily medicine that, if approved, would
potentially be the first in a new class of oral drugs (dipeptidyl
peptidase-4 [DPP-4] inhibitors) that enhances the body's own ability to
lower blood sugar (glucose) when it is elevated. The mechanism of action of
DPP-4 inhibitors is distinct from that of any currently available class of
glucose-lowering agents.


http://www.novonordisk.com/press/news/news.asp?sNewsTypeGUID=&lMonth=&lYear=&sLanguageCode=&sSearchText=&sShowNewsItemGUID=c43127a6-c7ff-475d-b200-bd3c361583a8&sShowLanguageCode=en-GB

Liraglutide, a once-daily GLP-1 analogue, shows potential to change course
of diabetes (14 Sep 2006)
Liraglutide phase 2 study shows increased insulin secretion and improved
blood glucose control in people with type 2 diabetes

Liraglutide, an investigational treatment for type 2 diabetes, improved the
ability of pancreatic beta cells to secrete insulin in people with type 2
diabetes, according to data presented today at the European Association for
the Study of Diabetes (EASD) conference.[1]

The findings from the study, part of a larger, double-blind,
placebo-controlled, randomised trial conducted over 14 weeks,[2]
specifically showed that liraglutide increased the maximum capacity of beta
cells to secrete insulin. In addition, first-phase insulin secretion, which
is diminished in patients with type 2 diabetes, was increased.

The main trial showed that liraglutide reduced levels of HbA1c, the primary
endpoint and a measure of a person's average blood glucose level over the
past two to three months. Additionally, participants on the highest dose of
liraglutide lost significantly more weight than did those on placebo by the
end of the 14-week study.

Here is a site with explanations :
http://www.glucagon.com/index.html

hth
Gys


.

Relevant Pages

  • Re: Vitamins and Diabetes- What Do You Take?
    ... I have read alot about diabetes and noted that a few sites have ... I get very high blood sugar readings.. ... You asked about supplements, so I will share what I have learned from ... Vitamin C - may improve T2 glucose tolerance and urinary protein loss. ...
    (misc.health.diabetes)
  • Re: Vitamins and Diabetes- What Do You Take?
    ... I have read alot about diabetes and noted that a few sites have ... I get very high blood sugar readings.. ... Vitamin C - may improve T2 glucose tolerance and urinary protein loss. ... I do take a few supplements, ...
    (misc.health.diabetes)
  • Re: confusing results
    ... I changed doctors and found a doctor who understood that any blood sugar at any time over 200 is diagnostic of diabetes (as stated in the ADA Diagnostic Criteria for the Diagnosis of Diabetes Mellitus). ... BTW, I turned out to have a genetic form of diabetes characterized by normal or near normal weight, near normal fasting blood glucose, and very high post-meal blood sugars. ...
    (alt.support.diabetes)
  • Re: The Ticking-Clock Hypothesis?
    ... Diabetes: The Ticking Clock) but could be misinterpreted as the focus was primarily the natural history of Metabolic Syndrome leading to full blown T2 Diabetes. ... For those who may not understand what an Hba1c measures and why it is so important, it is a measure of how much glucose has permanently bonded to proteins in blood cells. ... For people with this problem, there is another less well known test, the fructosamine test, which can show them the long term effects of high blood sugar on their blood. ...
    (alt.support.diabetes)
  • Re: What cxercise, vitamins, or food needed for diabetes/cardio risk individual?
    ... untreated Type 2 diabetes can cause you ... Glycation is the non-enzymic binding of glucose molecules to other molecules ... Animals fed chromium had lower fasting glucose and insulin levels and ... McCarty MF in Med Hypotheses 1994 Oct;43:253-65 PMID: ...
    (sci.med.cardiology)